Tag Archives: t

Top 10 Medical Stocks For 2018

Organovo Holdings Inc. (NASDAQ: ONVO) shares saw a handy gain on Tuesday after the bio-printer announced that it received a strong consumer response from its second tissue service. Specifically, the ExVive Human Kidney Tissue launched in September, which uses Organovos 3D bio-printed kidney tissue to study the effects of drug exposure through toxicology panels and transporter studies.

The company already has multiple commercial orders from several customers, including with two global, top 25 pharmaceutical companies.

For some background: Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.

Top 10 Medical Stocks For 2018: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

  • [By kiplinger]

     52-week high: $18.93 

    52-week low: $11.01 

    Annual revenues: $492.9 million 

    Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.

Top 10 Medical Stocks For 2018: Apartment Investment and Management Company(AIV)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Scripps Networks Interactive (SNI) sunk to the bottom of the S&P 500–narrowly beating out Apartment Investment and Management (AIV)–as the parent company of the Food Network and other channels gave back a chunk of its post-elections gains.

  • [By Ben Levisohn]

    Apartment Investment & Management (AIV) tumbled today, as the weakness in real-estate investment trusts following Donald Trump’s surprise election continued today. It was the second-biggest loser in the S&P 500 today.

    Getty Images

    Shares of Apartment Investment & Management dropped 4.1% to $41.03 today, while the Real Estate SPDR Dow Jones REIT ETF (RWR) fell 1.1% to $90.03. The S&P 500 rose rose 0.8% to 2,180.39.

    In a note released yesterday, Raymond James analyst Buck Horne and team cut their price target on Apartment Investment & Management to $50 from $50, even as they maintained their Strong Buy rating. They explain why:

    Prefacing our comment qualifying the significant economic uncertainties that have arisen post Tuesdays election, we are maintaining our Strong Buy rating onApartment Investment & Management shares while slightly adjusting our target price (to $50 from $52) and net-asset-value estimate (down $1 to $48.51/share). These adjustments are solely to reflect slightly more conservatism in our cap rate assumptions following the post-election interest rate shifts. We continue to find Apartment Investment & Managements risk/reward profile compelling in this environment as its diversified class B-priced portfolio should prove more resilient to supply pressures and benefit from the growing shortage of affordable workforce housing. In an inflationary environment with potentially declining housing affordability, we are particularly attracted to Aimcos price points, demographics, and balance sheet full of long-dated, non-recourse, fixed rate leverage.

    Apartment Investment & Management reported net income of $67 million on sales of $978 million in 2015.

Top 10 Medical Stocks For 2018: region(DGLD)

Advisors’ Opinion:

  • [By Jim Robertson]

    The VelocityShares 3x Inverse Gold ETN (NASDAQ: DGLD) seeks to provideshort exposure to three times (3x) the daily performance of theS&P GSCI Gold Index. As with UGLD, DGLD would be doing this viafutures contracts.

Top 10 Medical Stocks For 2018: Golden Star Resources Ltd(GSS)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Golden Star (NYSEMKT: GSS) is a gold mining and exploration company, and operates gold mines in Ghana, West Africa. GSS is up 396% YTD after it announced in July that it had begun pre-commercial production of gold in an underground mine in Ghana. GSS is trading at $0.825 per share on Monday intraday.

Top 10 Medical Stocks For 2018: Clean Diesel Technologies Inc.(CDTI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

    Sphere 3D Corp. (NASDAQ: ANY) is estimated to post a quarterly loss at $0.11 per share on revenue of $22.10 million.

Top 10 Medical Stocks For 2018: AltaGas Ltd. (ATGFF)

Advisors’ Opinion:


    AltaGas (OTCPK:ATGFF) recently announced that it’s going to acquire WGL Holdings (NYSE:WGL). This article will examine the financial side of the transaction. A number of Seeking Alpha authors have written articles on the merger as well, and I suggest that you read them.


    Regulators in California are behind a new business of providing utility-scale back-up battery storage at power generating facilities. Canadian-based AltaGas (OTCPK:ATGFF) recently announced a 10-year Energy Storage Resource Adequacy Purchase Agreement with Southern California Edison SCE, a subsidiary of Edison International (NYSE:EIX). A recap of the scope of the contract is described below, from ATGFF’s press release:

Top 10 Medical Stocks For 2018: YPF Sociedad Anonima(YPF)

Advisors’ Opinion:


    For the details of Knighthead Capital Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Knighthead+Capital+Management%2C+LLC

    These are the top 5 holdings of Knighthead Capital Management, LLCSPDR S&P 500 (SPY) – 1,500,000 shares, 57.03% of the total portfolio. Spirit Realty Capital Inc (SRC) – 9,113,000 shares, 11.82% of the total portfolio. New PositionYPF SA (YPF) – 2,153,795 shares, 7.26% of the total portfolio. Shares reduced by 1.5%TerraForm Global Inc (GLBL) – 9,200,000 shares, 6.61% of the total portfolio. EQT Corp (EQT) – 597,300 shares, 5.9% of the total p

Top 10 Medical Stocks For 2018: Clarke(t)

Advisors’ Opinion:

  • [By JJ Kinahan]

    Shares of AT&T Inc. (NYSE: T) were moderately lower while shares of Time Warner Inc (NYSE: TWX) headed to the upside in early trading today. Late yesterday, the Department of Justice (DoJ) surprised market observers by filing an antitrust lawsuit to block T’s $85.4 billion takeover of TWX. In the complaint, DoJ said the merger would harm competition, stifle innovation and drive up prices.

  • [By Laurie Kulikowski]

    Net operating cash flow has increased to $10,797.00 million or 23.76% when compared to the same quarter last year. In addition, AT&T INC has also modestly surpassed the industry average cash flow growth rate of 16.21%.

    The gross profit margin for AT&T INC is rather high; currently it is at 55.43%. Regardless of T’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 7.65% trails the industry average.


  • [By Chris Lange]

    24/7 Wall St. took a peek at plans from Verizon Communications Inc. (NYSE: VZ), AT&T Inc. (NYSE: T), T-Mobile US Inc. (NASDAQ: TMUS) and Sprint Corp. (NYSE: S). We have also provided some of the key highlights from each plan. In a separate post we looked at which companies offer the best service.


    With a dividend yield of 4.8%, AT&T (T) will continue to be an attractive income investment whether or not the merger with Time Warner (TWX) happens. AT&T recently completed other deals that have increased earnings and strengthened dividend safety.

Top 10 Medical Stocks For 2018: New Residential Investment Corp.(NRZ)

Advisors’ Opinion:

  • [By ]

    New Residential (NYSE: NRZ) is a U.S.-based REIT that specializes in managing investments in residential real estate. With a market cap of $5.5 billion, NRZ is one of the largest REITs in the United States, so this is no fly-by-night company. NRZ offers one of the best dividends in the industry. The trust made four dividend payments in 2017 totaling $1.94. That gives shares a current yield of 11.3%, more than a 400% premium to the S&P 500’s average 2.0% yield.

  • [By Lisa Levin]

    Ocwen Financial Corp (NYSE: OCN) shares were also up, gaining 42 percent to $3.25. New Residential Investment Corp (NYSE: NRZ) revealed it owned some servicing rights to the troubled Ocwen Financial. During today's conference call, New Residential’s executive suggested the company will pay $425 million for Mortgage Servicing Rights to Ocwen.

  • [By Sean Williams]

    Today’s lawsuit has spilled over to the company’s peers as well. New Residential Investment Corp. (NYSE:NRZ), which invests in excess mortgage servicing rights (MSRs), wound up falling as much as 13% during the day’s trading session. Ocwen is one of the three companies mentioned as being one of the primary servicers in New Residential Investment’s MSRs, according to its 10-K. If mortgage owners or bondholders terminate Ocwen as the servicer, the excess MSRs tied to Ocwen could lose some or all of their value.Altisource Portfolio Solutions S.A.(NASDAQ: ASPS)fell 42%.

  • [By Chris Dier-Scalise]

    Thge Vetr crowd upgraded its rating for New Residential Investment Corp (NYSE: NRZ) on Friday from the company's previous standing at 3 stars (Hold), issued 10 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly positive, with 80 percent of Vetr user ratings bullish.

Top 10 Medical Stocks For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

10 Dividend Stocks You Can Set and Forget

Tired of keeping a close eye on financial news and popping in and out of positions in an effort to get the most out of an increasingly volatile market?

If so, you’re not alone. There is a solution, however, for investors who’ve become mentally exhausted thanks to a bull market that has now persisted for a stunning nine years — just buy some dividend stocks and stop watching the market every day. Go find a new hobby instead. With some stocks, you really are better off just leaving them alone and letting time do the hard work for you.

With that as the backdrop, if you don’t know how or where to start a hunt for new income-oriented holdings, here’s a look at ten great dividend stocks that would at home in almost any investor’s portfolio. They’re all more reliable than average, and represent companies that can weather almost any storm.

In no certain order…

Dividend Stocks to Buy: AT&T (T) Dividend Stocks to Buy: AT&T (T)investorplace.com/wp-content/uploads/2016/04/tmsn2-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/04/tmsn2-73×40.jpg 73w, investorplace.com/wp-content/uploads/2016/04/tmsn2-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/04/tmsn2-250×137.jpg 250w, investorplace.com/wp-content/uploads/2016/04/tmsn2-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/04/tmsn2-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/04/tmsn2-160×88.jpg 160w, investorplace.com/wp-content/uploads/2016/04/tmsn2-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/04/tmsn2-100×55.jpg 100w,https://investorplace.com/wp-content/uploads/2016/04/tmsn2-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/04/tmsn2-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/04/tmsn2-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Mike Mozart via Flickr

Dividend Yield: 5.3%

Telecom giant AT&T Inc. (NYSE:T) is an oldie but a goodie, and with uncharacteristic weakness from the stock since the middle of 2016, the dividend yield has been pumped up to an impressive 5.3%. That’s a dividend that has been paid every quarter for the past few decades, by the way, and raised like clockwork every year since 1984.

Sure, AT&T has got headaches right now, even beyond its usual competition. The deal to pair up with Time Warner Inc (NYSE:TWX) hasn’t exactly been smooth sailing. Industry insiders are relatively certain it’s going to happen despite the DOJ’s interference though, and in that AT&T is leading the race to make 5G connectivity a reality, it should be able to keep its wireless competitors in check at the same time it ramps up enrollments in its streaming cable service DirecTV Now.

AT&T looks to be firing on all cylinders.

Dividend Stocks to Buy: Blackstone Group (BX) Dividend Stocks to Buy: Blackstone Group (BX)investorplace.com/wp-content/uploads/2017/05/bxmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/05/bxmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/05/bxmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/05/bxmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/05/bxmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/05/bxmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/05/bxmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/05/bxmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/05/bxmsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/05/bxmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

Dividend Yield: 6.9% over the past 12 months

Blackstone Group LP (NYSE:BX) isn’t a traditional company. In fact, it’s not a company at all. It’s an organization that owns and financially supports a variety of other companies, and in some cases gets involved in the management of them. It’s a private equity firm, but it’s so much more than just that.

Additionally, it’s good at what it does, and that’s good for income-seeking investors. While the dividend payout can vary unpredictably from one quarter to the next, broadly speaking it has been on the rise for quite some time, and a dividend of some sort has always been dished out. And if the economy heats and up in interest rates rise, much like a bank, that’s very good for Blackstone’s bottom line as it will eventually makes its way back into the pocket of shareholders.

The dividend yield of 6.8% over the last year, in the meantime, isn’t too shabby either.

Dividend Stocks to Buy: AmTrust Financial Services (AFSI) Dividend Stocks to Buy: AmTrust Financial Services (AFSI)investorplace.com/wp-content/uploads/2016/05/cashmsn2-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/05/cashmsn2-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: 401(K) 2012 via Flickr (Modified)

Dividend Yield: 6.6%

There aren’t any kinds of insurance AmTrust Financial Services Inc (NASDAQ:AFSI) doesn’t offer. In fact, life and health insurance are the only two major insurance markets AmTrust doesn’t dabble in.

That’s a two-edged sword, mind you. While the company has sidestepped the debacle of the ramifications of the Affordable Care Act and now the (more or less) end of it, Amtrust’s heavy reliance on catastrophic insurance policies meant it took a big hit when hurricanes Harvey and Irma took aim at the United States during the fall of last year. All told, the insurer swung from a profit of 61 cents per share in the same quarter a year ago to a loss of four cents per share in Q3 of 2017.

The resulting beat-down wasn’t necessary though, as it founded on a catastrophe the likes of which are rarely seen. The strong selloff from AFSI, however, has cranked its dividend yield up to a still-sustainable 6.6%.

Dividend Stocks to Buy: UBS Group (UBS) Dividend Stocks to Buy: UBS Group (UBS)investorplace.com/wp-content/uploads/2017/05/ubsmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/05/ubsmsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/05/ubsmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

Dividend Yield: 3.2%

When investors go on the hunt for dividend stocks within the financial sector, Zurich-based UBS Group AG (USA) (NYSE:UBS) usually isn’t a top-of-mind name. It should be though, now more than ever … It not only had a 3.2% yield, but also a 26-cent special dividend paid out in the past year.

There’s room for dividend growth too. Analysts are looking for 2017 earnings of $1.28 per share, up from 2016’s $1.17, which is projected to grow to $1.50 in 2018. And, only about 57% of its profits are currently being passed along to shareholders as dividends.

Dividend Stocks to Buy: Two Harbors (TWO) Dividend Stocks to Buy: Two Harbors (TWO)investorplace.com/wp-content/uploads/2017/10/mortgagemsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-91×50.jpg 91w,https://investorplace.com/wp-content/uploads/2017/10/mortgagemsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2017/10/mortgagemsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: House Buy Fast via Flickr

Dividend Yield: 11.9%

Two Harbors Investment Corp (NYSE:TWO) is anything but a household name. It’s not even a company. It’s an investment company, organized as a REIT, and is an obscure one at that. Don’t let the obscurity fool you though. There’s a lot of reliability packed into this obscure mortgage REIT package too, all the way back to 2010.

More important, things could heat up for this outfit sooner than most people are expecting. As Chief Investment Officer Bill Roth commented within the last quarterly report, “We are very excited about the opportunities we see emerging for our business. With the Fed reducing their reinvestments in Agency RMBS and mortgage spreads likely to widen, owning MSR is a significant benefit to our portfolio. Yet, at wider spreads, we believe there could be a tremendous investment opportunity to add Agencies.”

It’s currently yielding 11.9%.

Dividend Stocks to Buy: Iron Mountain (IRM) Dividend Stocks to Buy: Iron Mountain (IRM)investorplace.com/wp-content/uploads/2016/06/irmmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/06/irmmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/06/irmmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/06/irmmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/06/irmmsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/06/irmmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/06/irmmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/06/irmmsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/06/irmmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw,728px” />Source: Orin Zebest via Flickr

Dividend Yield: 6.3%

In a world that’s increasingly centered on the digital cloud, one would think the printed documents and literal signatures on forms would be a thing of the past. And to a large degree, things are moving in that direction. If you think paper is a thing of the past though, think again. The world is still printing like crazy, and organizations still need to store it all for a myriad of reasons.

Enter Iron Mountain Incorporated (Delaware) REIT (NYSE:IRM), which as its name implies, offers secure storage of physical files for organizations that are legally required to retain them. Iron Mountain helps companies make the move from physical to digital document management, helping them solve tricky compliance problems along the way.

It even offers document shredding solutions. In all cases though, it’s a wonderful recurring revenue business, easily supporting the dividend yield of 6.3%. That dividend grows pretty regularly too.

Dividend Stocks to Buy: BP (BP) Dividend Stocks to Buy: BP (BP)investorplace.com/wp-content/uploads/2017/05/bpmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2017/05/bpmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2017/05/bpmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2017/05/bpmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2017/05/bpmsn-400×220.jpg 400w, investorplace.com/wp-content/uploads/2017/05/bpmsn-116×64.jpg 116w, investorplace.com/wp-content/uploads/2017/05/bpmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2017/05/bpmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2017/05/bpmsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2017/05/bpmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Shutterstock

Dividend Yield: 5.6%

The future of BP Plc (ADR) (NYSE:BP) has more to do with the price of oil than how well the company itself is managed. But, both bode well for the company. Oil prices have rallied from less than $30 per barrel in early 2016 to a current price near $60 now, and though a little profit-taking is in the cards, the broad undertow remains a bullish one.

Crude’s rebound couldn’t have come at a better time for BP either. As of October, the dividend was and was expected to remain above per-share earnings. With crude well above BP’s breakeven price of around $47 as of August though, margins should start to widen quite nicely and leave decent-sized profit cushion for that dividend yield of 5.6%.

Dividend Stocks to Buy: Southern (SO) Dividend Stocks to Buy: Southern (SO)investorplace.com/wp-content/uploads/2016/04/somsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/04/somsn-73×40.jpg 73w, investorplace.com/wp-content/uploads/2016/04/somsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/04/somsn-250×137.jpg 250w, investorplace.com/wp-content/uploads/2016/04/somsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/04/somsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/04/somsn-160×88.jpg 160w, investorplace.com/wp-content/uploads/2016/04/somsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/04/somsn-100×55.jpg 100w,https://investorplace.com/wp-content/uploads/2016/04/somsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/04/somsn-78×43.jpg 78w, investorplace.com/wp-content/uploads/2016/04/somsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Desiree Kane via Flickr

Dividend Yield: 5%

No list of dividend stocks to buy would be complete without a utility stock, and no list of ownership-worthy utility stocks would omit Southern Co (NYSE:SO).

As to the former, utility stocks are cash-flow machines. In good economic times as well as bad, at a very minimum consumers keep their lights on by forking money over to their power supplier every month. As to the latter, Southern serves a total of 9 million customers peppered all across the nation, with plenty of exposure in the south and along the east coast. That kind of scale means a lot in the utility business.

It also smooths out any bumps and rough patches that could otherwise jeopardize its yield of 5%. It’s been reliably paid and steadily rising since 1948.

Dividend Stocks to Buy: Park Hotels & Resorts (PK) Dividend Stocks to Buy: Park Hotels & Resorts (PK)investorplace.com/wp-content/uploads/2016/09/officereitmsn-300×165.jpg 300w, investorplace.com/wp-content/uploads/2016/09/officereitmsn-55×30.jpg 55w, investorplace.com/wp-content/uploads/2016/09/officereitmsn-200×110.jpg 200w, investorplace.com/wp-content/uploads/2016/09/officereitmsn-162×88.jpg 162w, investorplace.com/wp-content/uploads/2016/09/officereitmsn-65×36.jpg 65w, investorplace.com/wp-content/uploads/2016/09/officereitmsn-100×55.jpg 100w, investorplace.com/wp-content/uploads/2016/09/officereitmsn-91×50.jpg 91w, investorplace.com/wp-content/uploads/2016/09/officereitmsn-78×43.jpg 78w,https://investorplace.com/wp-content/uploads/2016/09/officereitmsn-170×93.jpg 170w” sizes=”(max-width: 728px) 100vw, 728px” />Source: Anders Jildén via Unsplash

Dividend Yield: 7.7%

The name Park Hotels & Resorts Inc (NYSE:PK) may not ring a bell, but some of the hotels owned by this REIT will. It owns and operates, among others, several Hiltons, boasting 67 locales and 35,000 rooms… most aimed at the upper-scale traveler.

It doesn’t necessarily seem like the steadiest market to be in, but it’s more stable than one might imagine. A huge chunk of its hotels are in important business districts, and if the economy takes off the way it looks like it’s going to take off, that will keep Park Hotels & Resorts plenty busy for some time. Even if the economy doesn’t quite turn red-hot though, the yield of 7.7% is relatively well protected.

Dividend Stocks to Buy: Pfizer (PFE) Dividend Stocks to Buy: Pfizer (PFE)investorplace.com/wp-content/uploads/2017/10/pfemsn-300×150.jpg 300w, investorplace.com/wp-content/uploads/2017/10/pfemsn-768×384.jpg 768w, investorplace.com/wp-content/uploads/2017/10/pfemsn-60×30.jpg 60w, investorplace.com/wp-content/uploads/2017/10/pfemsn-200×100.jpg 200w, investorplace.com/wp-content/uploads/2017/10/pfemsn-400×200.jpg 400w, investorplace.com/wp-content/uploads/2017/10/pfemsn-116×58.jpg 116w, investorplace.com/wp-content/uploads/2017/10/pfemsn-100×50.jpg 100w, investorplace.com/wp-content/uploads/2017/10/pfemsn-78×39.jpg 78w, investorplace.com/wp-content/uploads/2017/10/pfemsn-800×400.jpg 800w,https://investorplace.com/wp-content/uploads/2017/10/pfemsn-170×85.jpg 170w” sizes=”(max-width: 950px) 100vw, 950px” />Source: Shutterstock

Dividend Yield: 3.7%

Last but not least, the 3.7% yield Pfizer Inc. (NYSE:PFE) currently offers doesn’t necessarily put it in the top echelon of dividend stocks, but what it lacks in income-producing potential it balances out with lots of growth potential.

One of those growth engines is Eucrisa. As Chris Lau pointed out last month, 60% of eczema patients using the treatment are repeat buyers. It could be a $2 billion drug at its peak pace. Meanwhile, arthritis drug Xeljanz is slated for an approval decision in March. Both offer new revenue stream potential.

In the meantime, its existing portfolio of products will continue to drive cash flow that funds what it pays back out to shareholders. This is the same company that owns staples like Advil as well as Lyrica, for the treatment of diabetic nerve pain and fibromyalgia.

Pfizer’s going to be fine.

As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley.

Compare Brokers

Top 10 Performing Stocks To Buy For 2018

March 16, 2017: Markets opened higher again Thursday but the uptick did not last longer. Within an hour shares had dropped and a brief turn higher was foiled quickly. The worst performing sectors for the day are utilities and healthcare, with financials showing the only decent gain. WTI crude oil for April delivery settled at $48.75 a barrel, down 0.2% on the day. April gold added 2.2% on the day to settle at $1,227.10. Equities were headed for a lower close shortly before the bell as the DJIA traded down 0.11% for the day, the S&P 500 traded down 0.22%, and the Nasdaq Composite traded down 0.02%.

The DJIA stock posting the largest daily percentage loss ahead of the close Thursday was E.I. du Pont de Nemours Inc. (NYSE: DD) which traded down 1.14% at $80.56. The stock’s 52-week range is $61.12 to $81.51. Volume was roughly 40% below the daily average of around 2.6 million shares. The company had no specific news.

Chevron Corp. (NYSE: CVX) traded down 1.00% at $107.79. The stock’s 52-week range is $92.25 to $119.00. Volume was about 10% below the daily average of around 6.3 million shares. The integrated oil & gas company had no specific news.

Top 10 Performing Stocks To Buy For 2018: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

Top 10 Performing Stocks To Buy For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Performing Stocks To Buy For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Top 10 Performing Stocks To Buy For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Top 10 Performing Stocks To Buy For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 10 Performing Stocks To Buy For 2018: Clarke(t)

Advisors’ Opinion:

  • [By Jim Robertson]

    DirecTV is a direct broadcast satellite service provider and is a subsidiary of AT&T Inc (NYSE: T). Its satellite service, launched on June 17, 1994, transmits digital satellite television and audio to households in the United States, Latin America and the Caribbean withprimary competitorsbeing Dish Network and cable television providers. On July 24, 2015, after receiving approval from the FCC and United States Department of Justice, AT&T acquired DirecTV in a transaction valued at $48.5 billion. DirecTV would be paying$1.5 billion a year for the NFL Sunday Ticket.AT&T’s shares may have broken out of a downtrend:

  • [By Brian Feroldi, Dan Caplinger, Rich Duprey, Jason Hall, and Jordan Wathen]

    In order to point you in the right direction, we asked a team of Fools to highlight a dividend stock that they feel is a great stock for a beginner. Read on to see why they picked AT&T (NYSE:T),Apple (NASDAQ:AAPL),Anheuser-Busch InBev(NYSE:BUD), Mastercard(NYSE:MA), andJPMorgan Chase(NYSE:JPM).

  • [By Paul Ausick]

    AT&T Inc. (NYSE: T) dropped about 1.4% Tuesday to post a new 52-week low of $35.87 after closing Monday at $36.39. The 52-week high is $43.50. Volume was around 5.8 million shares traded, nearly 10 times the daily average of around 600,000. The company had no specific news.

  • [By Douglas A. McIntyre]

    At the other end of the iPhone 8 spectrum, wireless companies like AT&T Inc. (NYSE: T) probably will price the low-end version of the iPhone 8 below $40 a month, with 24-month contracts. This kind of price plan is a usual way for large wireless carriers to get and hold customers for long periods. Even if the carrier pays a lot for the smartphone, it presumably makes that back in monthly fees and on people who renew their subscriptions for a longer period.

  • [By Chris Lange]

    AT&T Inc.’s (NYSE: T) second-quarter results are scheduled for Tuesday. The consensus earnings estimate is $0.74 per share, on $39.82 billion in revenue. The shares were last seen at $36.51. The consensus price target is $40.27, and the 52-week trading range is $35.81 to $43.50.

Top 10 Performing Stocks To Buy For 2018: Snap-On Incorporated(SNA)

Advisors’ Opinion:


    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 


    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

Top 10 Performing Stocks To Buy For 2018: PRA Group, Inc.(PRAA)

Advisors’ Opinion:

  • [By Lee Jackson]

    PRA Group Inc. (NASDAQ: PRAA) has been hit hard recently, and shareholders may be glad to know that a director took advantage of the sell-off and stepped in to buy shares. That board member bought 143,000 shares of the financial and business services company at prices that ranged from $34.40 to $34.89. The total for the buy was set at $5 million. The stock closed Friday at $32.90, in a52-week range of $21.93 to $42.70. The consensus price target is $40.60.

Top 10 Performing Stocks To Buy For 2018: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.


  • [By Peter Graham]

    A long term performance chart shows shares ofmid cap Sanderson Farms more than doubling in value while large cap Tyson Foods, Inc (NYSE: TSN)has more than tripled in value and mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) has quadrupled in value:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Sanderson Farms doubling in value while mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) and large cap Tyson Foods, Inc (NYSE: TSN) have been even better performers albeit shares are below their peaks and have been somewhat volatile:

Top 10 Performing Stocks To Buy For 2018: Oasis Petroleum Inc.(OAS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Oasis Petroleum Inc. (NYSE: OAS) were down 14 percent to $8.60 after the company reported a 32 million share common stock offering. The company announced Delaware Basin acquisition for $946 million and also raised its Q4 production guidance.

  • [By Jon C. Ogg]

    Oasis Petroleum Inc. (NYSE: OAS) rose a whopping 27.8% to $14.98, and the 33.2 million shares was about 2.5 times normal volume. Oasis Petroleum has a 52-week trading range of $3.40 to $15.02 and a consensus analyst price target of $14.54. The company has a total market cap of $3.5 billion.

  • [By Chris Lange]

    Oasis Petroleum Inc. (NYSE: OAS) shares slid on Tuesday after the company announced that it would be buying into the Delaware Basin. Analysts seemed to applaud this move, despite investors sending shares into the fire. Jefferies raised its price target to $14 from $13, and Morgan Stanley raised its target to $11 from $9. RBC has an Outperform rating and raised its target to $14 from $13, while SunTrust Robinson Humphrey downgraded it to Hold from Buy. Shares were down about 14% at $8.67, in a 52-week range of $6.69 to $16.73.

  • [By Paul Ausick]

    Oasis Petroleum Inc. (NYSE: OAS) is rated a Buy and the price target was lifted to $24. For 2017, the net loss estimate improved from a prior $0.27 per share to $0.23 per share. The 2018 EPS estimate rose from $0.62 to $0.64. Shares closed at $14.13 on Friday. The 52-week range is $5.93 to $14.35, and the consensus 12-month target is $17.87.

  • [By Craig Jones]

    Jon Najarian spoke on CNBC’s “Fast Money Halftime Report” about unusually high options activity in Oasis Petroleum Inc. (NYSE: OAS).

    Traders bought around 10,000 contracts of the June 10 calls in the first half of the trading session on Thursday. The trade is unusual because the average options volume in the name is a few hundred contracts. Najarian bought the calls and is planning to hold them for two weeks.

good stocks to invest in today

Overall, 29 states (including D.C.) have medical marijuana laws on the books and eight states have embraced recreational marijuana markets. Creating those markets is complex, but tax revenue statistics suggest the effort is worth it. Marijuana advisory firm GreenWave Advisors estimates marijuana sales taxes added $1.6 billion to state tax receipts last year,and GreenWave’s Matt Karnes estimates that by 2021, marijuana sales taxes could total more than $4 billion.

Racking up revenue

Pro-pot advocates have used state tax revenue from marijuana sales as a major selling point to win support, and so far, their claims of billions of additional dollars in tax revenue appear to be spot on.


In 2016, GreenWave Advisors pegs total retail marijuana sales of $6.5 billion, up 35% from 2015, including recreational marijuana sales of $1.8 billion. Medical marijuana sales remain the bigger of the two markets, with California accounting for the lion’s share of sales. Californians voted to open up a recreational market last November, so that revenue mix could change over the next few years.

good stocks to invest in today: Finisar Corporation(FNSR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Finisar Corporation (NASDAQ: FNSR) shares dropped 21 percent to $27.46 after the company reported weaker-than-expected results for its third quarter and issued disappointing forecast for the current quarter.

  • [By Evan Niu, CFA]

    Shares of optical component companies have dropped today, includingOclaro (NASDAQ:OCLR), Acacia (NASDAQ:ACIA), Lumentum (NASDAQ:LITE), and Finisar (NASDAQ:FNSR), whose shares were down 11%, 11%, 6%, and 3%, respectively, as of 3:30 p.m. EDT, after the U.S. broadened its investigation regarding compliance with sanctions programs.

  • [By Renu Singh]

    Finisar’s (FNSR) datacom segment generated $184.4 million in revenue in the last reported quarter. This was a sequential growth of 9.3%. The Ten Gigabit Ethernet or 10GbE modules contributed about 40% to the datacom segment’s revenue. As organizations go digital, there are an increasing number of applications that require considerable bandwidth to support the transfer of large data, video, and audio files across networks. Using 10GbE optical links provides sufficient bandwidth to support these bandwidth-intensive applications at a lower cost.

good stocks to invest in today: Leading Brands Inc(LBIX)

Advisors’ Opinion:

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares dropped 13 percent to $1.99 following Q2 results. Leading Brands posted Q2 EBITDAS of $0.00 per share, compared to $0.09 per share during the same period last year.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares shot up 66 percent to $2.49 following Q1 results. Leading Brands reported Q1 earnings of $0.10 per share on revenue of $3.033 million.

  • [By Lisa Levin]

    Leading Brands, Inc (USA) (NASDAQ: LBIX) shares were also up, gaining 145 percent to $3.31 on no formal news from company. The stock rallied 215 percent over Tuesday and Wednesday of this week amid trader speculation stock could be sympathy play on move higher in Helios & Matheson. However, Leading Brands shares sold off 27 percent on Thursday.

good stocks to invest in today: QC Holdings Inc.(QCCO)

Advisors’ Opinion:

  • [By Monica Gerson]

    QC Holdings (NASDAQ: QCCO) shares tumbled 2.58% to reach a new 52-week low of $2.27. QC Holdings’ trailing-twelve-month profit margin is 0.60%.

    NewLead Holdings (NASDAQ: NEWL) shares dipped 6.56% to touch a new 52-week low of $0.08 after the company completed the acquisition of titles in the Viking Mine located in Kentucky, USA.

good stocks to invest in today: Clarke(t)

Advisors’ Opinion:


    If youre looking at dividend stocks, then you cant ignore the telecommunications sector. Once you do, youve got to put AT&T Inc. (T) on the list too.


    Finding a bottom after a long decline can be incredibly lucrative, Cramer told viewers, as was the case in 2009 when he set his sights on AT&T (T) as about the most bulletproof recommendation he could muster.

  • [By Ashley Moore]

    The problem came in Q4. Time Warner started adjusting out the costs of the AT&T Inc. (NYSE: T) merger. This is something investors should note.

  • [By Adam Levy]

    As more consumers cut the cord, competition in the pay-TV industry is growing increasingly fierce. That’s led some companies to seek consolidating acquisitions like AT&T (NYSE:T) did last year by buying DIRECTV. Others, meanwhile, have sought to attract subscribers with low-priced bundles and over-the-top packages like DISH Network’s (NASDAQ:DISH) Sling TV.

  • [By Elizabeth Balboa]

    It’s happened to AT&T Inc. (NYSE: T). It’s happened to Citigroup Inc (NYSE: C). It’s happened to Chevron Corporation (NYSE: CVX), General Motors Company (NYSE: GM) and Sears Holdings Corp (NASDAQ: SHLD)'s predecessor Sears, Roebuck & Co.

  • [By Paul Ausick]

    AT&T Inc. (NYSE: T) dropped about 1.4% Tuesday to post a new 52-week low of $35.87 after closing Monday at $36.39. The 52-week high is $43.50. Volume was around 5.8 million shares traded, nearly 10 times the daily average of around 600,000. The company had no specific news.

good stocks to invest in today: Ford Motor Company(F)

Advisors’ Opinion:

  • [By Daniel Miller]

    Another Ford Motor Co. (NYSE:F) earnings conference call, and another day of confused and volatile trading!

    The market has generally had a tough time digesting Ford’s results recently in light of peak auto sales, one-time charges, and other one-off events. Thursday’s first-quarter report was no different: In pre-market trading, the stock rose about 2.5% after its initial results topped estimates, then promptly gave back those gains and then some. Here’s what’s going on with Ford, and some important factors for investors to remember.

  • [By Paul Ausick]

    Ford Motor Co. (NYSE: F) dropped about 1% Friday to post a new 52-week low of $10.90 after closing at $11.01 on Thursday. The stock’s 52-week high is $14.04. Volume was about 30% below the daily average of around 39 million shares. The company had no specific news Friday.

  • [By Ben Levisohn]

    U.S. automakers Ford Motor (F) and General Motors (GM) reported their December U.S. sales today–and went a long way towards dispelling concerns that sales were headed for a rapid decline. The numbers were good enough, in fact, that CFRA Research’s Efraim Levy kept his Strong Buy rating on General motors. He explains why:

    Getty Images

    Led by GM’s Dec. 10% year-to-year new light vehicle sales gain, Toyota’s (TM) 2.0% growth and Ford’s (F) 0.3% increase, the auto industry should report its 7th straight year of expansion. While we see ’16 as the peak, as we project a 1.5% to 2.0% volume dip for ’17, we see positives. We see economic growth, higher consumer confidence, a strong stock market and moderate gas prices among factors driving a favorable shift to higher margins trucks and SUVs. We see a healthy sales plateau above 17M units through ’18. We find GM attractive for total return potential.

    Shares of General Motors have climbed 5.1% to $36.94 at 12:43 p.m. today, while Ford Motor has jumped 5.1% to $13.23, and Toyota Motor (TM) has risen 1.8% to $120.72.

good stocks to invest in today: TTM Technologies, Inc.(TTMI)

Advisors’ Opinion:

  • [By Anders Bylund]

    How do you pick the top names in this broadly lucrative industry? I’m here to show you my three favorites in the printed circuit board market: Sanmina (NASDAQ:SANM), Benchmark Electronics (NYSE:BHE), and TTM Technologies (NASDAQ:TTMI), each one tailor-made for a different type of investor.

  • [By Evan Niu, CFA]

    Shares of circuit board manufacturer TTM Technologies (NASDAQ:TTMI) have jumped today, up by 10% as of 3 p.m. EST, after the company reported fourth-quarter earnings.

Hot Low Price Stocks For 2018

Small SUVs are the hottest segment in the new car market right now. So maybe it shouldn’t be surprising that a big chunk of the new vehicle unveilings at the Los Angeles Auto Show were little crossover SUVs.

It seemed like there was an SUV popping out every time you turned around. For starters, Ford unveiled its new EcoSport just before the show with DJ Khaled doing the honors.

The Jeep Compass is another example of the car market’s madness for small-sized SUVs. The current version is a strong seller despite abysmal reviews. Consumer Reports gave it the lowest rating of any compact SUV and Car & Driver awarded it a mere 1.5 out of a possible five stars.

And yet, as of last month, Jeep Compass sales for the year were up 44%. According to Fiat Chrysler Automobiles (FCAM), which makes Jeeps, the sales jump reflects the Compass’s relatively low price given all the desirable SUV features that it offers.

DJ Khaled unveils new Ford EcoSport on Snapchat

It’s too soon to know, of course, how good the new Compass is but it should at least be a vast improvement over the outgoing model. Since it’s a Jeep, engineers took off-road capability seriously in creating the new Compass. Two different full-time all-wheel-drive systems are available including a super-slow off-road “crawl” gearing ratio. “Trail Rated” versions can wade through 19 inches of water and climb over steep hills and out of tight ditches. At the same time, Jeep also promises better on-road behavior.

Hot Low Price Stocks For 2018: Clarke(t)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    At the other end of the iPhone 8 spectrum, wireless companies like AT&T Inc. (NYSE: T) probably will price the low-end version of the iPhone 8 below $40 a month, with 24-month contracts. This kind of price plan is a usual way for large wireless carriers to get and hold customers for long periods. Even if the carrier pays a lot for the smartphone, it presumably makes that back in monthly fees and on people who renew their subscriptions for a longer period.

  • [By Chris Lange]

    AT&T Inc. (NYSE: T) first-quarter results are scheduled for Tuesday. The consensus earnings estimate is $0.74 per share, on $40.57 billion in revenue. The shares were last seen at $39.93. The consensus price target is $42.80, and the 52-week trading range is $36.10 to $43.89.

  • [By Laurie Kulikowski]

    After a year of stock price fluctuations, the net result is that T’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The stock’s price rise over the last year has driven it to a level which is somewhat expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.


  • [By Brian Stoffel]

    It’s important to remember that AT&T (NYSE:T) is more than just the namesake brand. The company also owns DirecTV, and it may soon acquireTime Warner (NYSE:TWX)if regulators approve the deal.

  • [By ]

    Of course we were familiar with the power of the compounding growth of dividend reinvestment. As you can see from the chart below, if you invested $20,000 in securities paying a 7% yield, after 10 years your portfolio would be worth $39,343 with reinvested dividends. And if your holdings happened to boost their dividends by just 5% annually — something even giant blue chip AT&T (NYSE: T) has been able to beat — your portfolio would be sitting at $46,475. That’s an increase of 132.4%. And that’s assuming zero capital gains. That isn’t bad, especially when you consider the S&P 500 Index lost 26.5% in the ten-year period ended in 2009.


    AT&T Inc. (T) currently yields 4.7% and pays a 48-cents-per-share quarterly dividend. Since 2008, T has been upping its quarterly dividend by $0.01 per year.

Hot Low Price Stocks For 2018: McKesson Corporation(MCK)

Advisors’ Opinion:

  • [By ]

    McKesson Corporation (NYSE: MCK) is the largest wholesale distributor of pharmaceuticals, counting CVS and Walmart as major customers. Along with rivals Cardinal Health and AmerisourceBergen, the three control 90% of the $300 billion retail pharmaceutical distribution market.

  • [By Dan Caplinger]

    Drug-distribution specialist McKesson (NYSE:MCK) has had a tough year. Even as the overall stock market has climbed, the company’s shares have suffered, as investors fear that any business related to pharmaceuticals will have a political target on its back even under the current administration. Last quarter’s sluggish numbers didn’t create much enthusiasm for McKesson either.

  • [By Ben Levisohn]

    Clinton 15 stock basket (DBUSCLNT): UnitedHealth Group (UNH), Humana (HUM), McKesson (MCK), Aecom (ACM), Quanta Services (PWR), ExxonMobil (XOM), Alcoa (AA), NextEra Energy (NEE), Cree (CREE), First Solar (FSLR), Facebook (FB), Netflix (NFLX), Prudential Financial (PRU), Citigroup (C), Union Pacific (UNP).

  • [By Ben Levisohn]

    Leerink’s David Larsen and Matt Dellelo traces today’s big gain to Amerisource’s big drop following McKesson’s (MCK) earnings last week:

  • [By Douglas A. McIntyre]

    McKesson Corp. (NYSE: MCK), the leading pharmaceutical distributor, posted a revenue increase in the past year of $49.7 billion, up from $47.5 billion in ayear earlier. Its management offered hefty earnings for the quarter and year ahead. It continues to be a buyer of other companies, most recently Change Healthcare (which was labeled a merger with one of McKesson’s divisions). The current dividend is $1.12, or 0.61%.

Hot Low Price Stocks For 2018: Silicon Laboratories Inc.(SLAB)

Advisors’ Opinion:

  • [By Lisa Levin]


    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

Hot Low Price Stocks For 2018: Alphabet Inc.(GOOGL)

Advisors’ Opinion:

  • [By Keith Speights, Brian Stoffel, and George Budwell]

    Healthcare is changing rapidly. Which companies will emerge as the huge winners with these major changes? We asked three of our healthcare contributors to weigh in on the subject. Here’s whyAbbVie (NYSE:ABBV),Alphabet (NASDAQ:GOOGL) (NASDAQ:GOOG), Johnson & Johnson (NYSE:JNJ), and Veeva Systems (NYSE:VEEV) could represent bold bets on the future of healthcare.

  • [By Sreekanth Anasa]

    Shares of Mountain View, California-based Alphabet Inc (NASDAQ:GOOGL)have largely underperformed the FANG stocks this year. GOOGL stock did make a bright start to the year gaining more than 7% in the first two months, far better gains than that in the whole of 2016, but the stocklost momentum after the YouTube Ad controversy. The search giant Google’s parent company Alphabet’s stock is still down more than 2% compared to a month ago. It appears that the YouTube Ad controversy did weigh heavy on GOOGL stock. Alphabet stock, as of yesterday (April 18), has made marginal gains since the company’s last earnings when it had missed the estimates. With Q1 earnings around the corner, the question arises whether GOOGL stock could build some momentum and resume its uptrend ahead of the latest earnings. Let’s take a closer look.

  • [By Shudeep Chandrasekhar]

    At the end of Q1 2017, Microsoft had $136.932 billion cash on hand, while their total liabilities stood at $142.152 billion. Microsofts short-term debt was $14.5 billion and long-term debt was $60.15 billion. Even if Microsoft decided to bring back cash from overseas and pay 40% tax on it, they would be able to clear all their short term and long term debt and still be left with billions in hand. Apple Inc(NSDQ:AAPL), Microsoft and Alphabet Inc (NSDQ:GOOGL) – all three companies are sitting on a mountain pile of cash that will allow them to plow it back into the business when necessary, making big, bold acquisitions as and when required.

  • [By Sreekanth Anasa]

    Facebook Inc. (NSDQ:FB) stock has been down more than 3% over the last one month as the fake news and overstatement of metrics issue has done considerable damage to its reputation. However, advertisers are not going to flee its platform. Infact,Facebook is slowly taking the fight to industry leaderAlphabet Inc’s (NSDQ:GOOGL) YouTube in online video space and digital video-related advertising.According to aCisco Forecast, videos will represent 69% of all consumer-based Internet traffic by 2017; this is expected to rise to 80%by 2019. Facebook acknowledges this and way back in April, it announced Facebook Live, allowing people and pages to post live videos on the site. It has been working hard to undermine YouTube’s supremacy, the undisputed ruler of web video. But here’s how things may change for Facebook and FB stock.

  • [By Adam Levine-Weinberg]

    Last week, Brand Finance came out with its annual listing of brand valuations. In a somewhat shocking finding, the consulting group declared that Apple (NASDAQ:AAPL) had lost its supremacy to Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL) subsidiary Google.